| Date Filed | Type | Description |
| 02/10/2014 |
SC 13G/A
| AQR CAPITAL MANAGEMENT LLC reports a 0% stake in BioMimetic Therapeutics, Inc. |
| 03/18/2013 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 03/18/2013 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 03/13/2013 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/11/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/11/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/11/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/11/2013 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments |
| 03/11/2013 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement |
| 03/06/2013 |
8-K
| Quarterly results |
| 03/01/2013 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities |
| 02/26/2013 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 02/12/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 02/12/2013 |
8-K
| Other Events |
| 01/23/2013 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition |
| 01/14/2013 |
8-K
| Other Events |
| 01/08/2013 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 01/07/2013 |
8-K
| Other Events |
| 01/03/2013 |
8-K
| Other Events, Financial Statements and Exhibits |
| 01/03/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 12/21/2012 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 12/03/2012 |
SC 13D/A
| Novo A/S reports a 16.7% stake in BioMimetic Therapeutics, Inc. |
| 11/29/2012 |
SC 13D
| BIOMIMETIC THERAPEUTICS, INC. reports a 36% stake in BioMimetic Therapeutics, Inc. |
| 11/27/2012 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 11/19/2012 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 11/19/2012 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 11/19/2012 |
425
| Form 425 - Prospectuses and communications, business combinations |
| 11/06/2012 |
8-K
| Quarterly results|
Docs:
|
"BioMimetic Therapeutics, Inc. Reports Third Quarter 2012 Financial Results Franklin, Tenn. – November 5, 2012 – BioMimetic Therapeutics, Inc . today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011. For the nine months ended September 30, 2012, the Company reported a net loss of $17.1 million, or $0.61 per diluted share, compared to a net loss of $23.3 million, or $0.83 per diluted share, for the same period in 2011. The Company ended the quarter with $44.3 million of cash, cash equivalents and investm..." |
|
| 11/05/2012 |
10-Q
| Quarterly Report for the period ended September 30, 2012 |
| 09/18/2012 |
8-K
| Other Events |
| 09/04/2012 |
EFFECT
| Form EFFECT - Notice of Effectiveness |
| 08/14/2012 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933 |
| 08/02/2012 |
10-Q
| Quarterly Report for the period ended June 30, 2012 |
| 07/09/2012 |
8-K
| Form 8-K - Current report |
|